Innovations in Gene Editing Technology
The continuous improvement of CRISPR-CAS systems, such as improved specificity, lower off-target effects, and the creation of new gene-editing platforms like base editing and prime editing, strongly propels market expansion. This technological advancement expands the use of CRISPR from simple research to complex therapeutic applications. For instance, federal funding for genomics research, which largely encompasses gene editing technologies, has consistently risen, demonstrating ongoing governmental support in this area, as reported by the National Institutes of Health (NIH). These ongoing advancements bolster trust in the safety & efficacy of CRISPR, driving its clinical translation & wider adoption across pharmaceutical and academic communities.
Growing Incidence of Genetic Disease
The increasing prevalence of genetic & incurable diseases, including cystic fibrosis, sickle cell anemia, and cancers, largely drives the need for CRISPR-based diagnostic and therapeutic applications. CRISPR provides unmatched specificity for correcting disease-causing mutations at the genetic level, holding the potential for curative approaches where conventional therapies are ineffective. The World Health Organization estimates millions of people are affected by genetic disorders across the globe and that about 1 in 300 new borns receive a diagnosis for a genetic or congenital disorder. Such a high burden of disease necessitates the need for more sophisticated genetic therapies, and hence CRISPR is a key technology to fill the unmet medical needs and advance patient care.
Expansion into Non-Therapeutic Applications
CRISPR technology has great promise outside of human therapeutics in agriculture, industrial biotechnology, and diagnostics. In agriculture, it allows for targeted crop trait improvement for higher yield, disease resistance, and nutritional content, responding to global food security issues. For instance, the US Department of Agriculture (USDA) has already approved several gene-edited crops for commercialization, reflecting clear regulatory progress & market uptake. In diagnostics, CRISPR-based solutions enable quick, precise, and economical detection of pathogens & genetic markers. The extensive applications open enormous untapped markets and make CRISPR a general-purpose tool with widespread societal impact & commercialization potential.
Increased Investment in Research & Development
The CRISPR market is supported by rising public and private investments in research and development to discover new applications, enhance current technologies, and develop clinical pipelines. Venture capital investments in gene editing companies have increased markedly, reflecting high confidence from investors in the commercial viability of the technology. In addition, government agencies across the world are awarding massive grants for genomics & biotechnology research. This funding facilitates rigorous preclinical and clinical trials, promotes academic-industrial partnerships, and facilitates the exploration of new CRISPR-based products and medicines. Such ongoing R&D investment is important for overcoming existing technological barriers and enlarging the market's reach.
The following Key Market Indicators present a comprehensive overview of the social and economic landscape of the selected region, offering critical insights into market-specific trends and developments. These indicators, combined with data from government statistics, industry associations, and corporate sources, form the analytical foundation of NextGen Intelligence Stats' market models.
| Aspects | Details |
Base Year
|
2024 |
Historic Data
|
2021-2023 |
Forecast Period
|
2025-2035 |
Regions & Countries Covered
|
North America (United States, Canada), Europe (Germany, France, Italy, United Kingdom, Spain, Rest of Europe), Asia Pacific (China, Japan, South Korea, India, Rest of Asia Pacific), Latin America (Brazil, Argentina, Rest of Latin America), Middle East& |
Companies Profiles
|
|
Segmentation Level Customization
|
Additional Segments and Sub Segment |
Company Level Customization
|
Market share analysis at country levels |
Country level Data Customization
|
Segmental volume analysis Pricing Analysis of Product Company Market Share |
October 2024: CRISPR Therapeutics AG and Vertex Pharmaceuticals revealed new encouraging clinical data with exa-cel (Casgevy) for sickle cell disease & transfusion-dependent beta thalassemia, again promoting further its efficacy and safety profile in long-term follow-up research, endorsing its promise as a one-time functional cure.
September 2024: Intellia Therapeutics, Inc. disclosed encouraging interim results from its Phase 1 trial of NTLA-2001 in transthyretin (ATTR) amyloidosis, demonstrating prolonged deep decreases in serum TTR protein levels following a single dose, demonstrating the promise of in vivo CRISPR gene editing for systemic disorders.
April 2024: Thermo Fisher Scientific, Inc. launched a new CRISPR analytical workflow solution that combines state-of-the-art instrumentation with bespoke software to simplify characterization and validation of gene-edited cells for research and clinical use, making high-throughput genomic analysis more efficient.
November 2023: Genscript Biotech Corporation diversified its CRISPR service portfolio by adding state-of-the-art gRNA library synthesis and screening services, enabling large-scale functional genomics research and drug target discovery activities for biotech and pharma clients worldwide.
The CRISPR market is a mix of large, established life science companies and upstart gene-editing biotechnology companies. The dominant players such as Thermo Fisher Scientific, Inc. and Merck KGaA mainly provide CRISPR tools, reagents, and services to serve the research & development requirements of academia and industry customers. Firms like CRISPR Therapeutics AG, Editas Medicine, Intellia Therapeutics, Inc., and Beam Therapeutics Inc. are leading the charge to develop CRISPR-based gene therapies for many genetic diseases, with several clinical trials ongoing to treat diseases like sickle cell disease &transthyretin amyloidosis. Competitive strategies are centred on significant R&D investments to improve gene-editing efficiency & accuracy, build therapeutic pipelines, and acquire intellectual property. Strategic partnerships & collaborations are prevalent, allowing firms to tap into complementary competence & speed up product development. For example, partnerships between therapeutic developers and tool providers allow translation of research tools into clinical use.
• Thermo Fisher Scientific
• Merck KGaA
• Agilent Technologies
• Genscript Biotech Corporation
• CRISPR Therapeutics
• Editas Medicine
• Intellia Therapeutics
• Beam Therapeutics
• Caribou Biosciences
• Lonza Group
• Danaher Corporation
• PerkinElmer
• Hera Biolabs
• OriGene Technologies
• Cellecta
• Mammoth Biosciences
• Applied StemCell
• New England Biolabs
• ToolGen
• GeneCopoeia
• Others
Industry forecasts indicate that the global CRISPR market will register consistent expansion, with market value projected to escalate from US$ 7.82 billion in 2024 to approximately US$ 46.10 billion by 2035, growing at a CAGR of 15.1%.
The Global CRISPR Market is poised to grow at a CAGR of 15.1% from 2025 to 2035.
Innovations in Gene Editing Technology, Growing Incidence of Genetic Disease, Expansion into Non-Therapeutic Applications, Increased Investment in Research & Development
North America accounted for 32.60% share in the CRISPR market.
North America CRISPR Market share, 2024
Source: NextGen Intelligence Stats and Consulting LLP
North America accounted for 32.60% share in the CRISPR market. This is owing to tremendous investments in biotechnology R&D, a strong presence of leading market players, supportive regulatory environments, and sophisticated healthcare infrastructure, especially in the US. The area has a high density of academic research centers and pharmaceutical firms actively involved in CRISPR-based drug development and clinical trials. The Asia-Pacific is expected to be the most rapidly growing region in the CRISPR market with a predicted CAGR of 18.4% during the forecast period. This high growth is driven by rising governmental investments in genomic research, growth in prevalence of genetic and chronic diseases, increasing healthcare spending, and rising numbers of strategic partnership between global and local participants. These nations, such as China, Japan, and India, are becoming key contributors based on their patient populations, growing R&D facilities, and favourable government policies towards biotechnology innovation.
1.1. Introduction
1.2. Report Description & Objective
1.3. Years Considered For Study
1.4. Assumption And Limitation
2.1. Data Collection
2.2. Primary Research & Secondary Research
2.3. Bottom-Up Approach & Top-Down Approach
2.4. Market Analysis & Size Estimation
2.5. Quality Check & Final Review
3.1. Report Scope
3.2. Executive Summary
4.1. Top Trends To Watch
4.2. Top Strategies Followed By Key Players
4.3. Top Investment Pockets
5.1. Market Definition
5.2. Market Drivers
5.3. Market Restraints & Challenges
5.4. Market Opportunities
6.1. Porter’s Five Forces’ Analysis
6.2. Value Chain Analysis / Supply Chain Analysis
6.3. PESTLE Analysis
6.4. Regulatory Landscape
6.5. Pricing Analysis
7.1. Global CRISPR Market, By Product & Services
7.2. Global CRISPR Market Attractiveness, By Product & Services
7.2.1. CRISPR Kits & Enzymes
7.2.2. CRISPR Libraries
7.2.3. Other Products
7.2.4. gRNA Design & Vector Construction
7.2.5. Cell Line Engineering
7.2.6. Screening Services
7.2.7. Other Services
8.1. Global CRISPR Market, By Application
8.2. Global CRISPR Market Attractiveness, By Application
8.2.1. Drug discovery & development
8.2.2. Agriculture
8.2.3. Others
9.1. Global CRISPR Market, By End User
9.2. Global CRISPR Market Attractiveness, By End User
9.2.1. Pharmaceutical & biotechnology companies
9.2.2. Academic & research institutes
9.2.3. Others
10.1. Global CRISPR Market, By Geography
10.2. Global CRISPR Market Attractiveness, By Geography
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Middle East & Africa
10.2.5. Latin America
11.1. North America Market Overview, By Countries
11.2. Market Overview, By Type
11.3. Market Overview, By Application
11.3.1. United States
11.3.2. Canada
12.1. Europe Market Overview, By Countries
12.2. Market Overview, By Type
12.3. Market Overview, By Application
12.3.1. Germany
12.3.2. France
12.3.3. UK
12.3.4. Italy
12.3.5. Spain
12.3.6. Rest of Europe
13.1. Asia Pacific Market Overview, By Countries
13.2. Market Overview, By Type
13.3. Market Overview, By Application
13.3.1. India
13.3.2. China
13.3.3. Japan
13.3.4. Latin Korea
13.3.5. Rest of Asia Pacific
14.1. Middle East & Africa Market Overview, By Countries
14.2. Market Overview, By Type
14.3. Market Overview, By Application
14.3.1. GCC
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
15.1. Latin America Market Overview, By Countries
15.2. Market Overview, By Type
15.3. Market Overview, By Application
15.3.1. Brazil
15.3.2. Argentina
15.3.3. Rest of Latin America
16.1. Key Developments
16.1.1. Partnerships, Collaborations, Agreements
16.1.2. Mergers & Acquisitions
16.1.3. New Product Developments
16.1.4. Other Developments
16.2. Company Share Analysis
16.3. Company Profiles
16.3.1. Thermo Fisher Scientific, Inc.
16.3.1.1. Company Overview
16.3.1.2. Product Overview
16.3.1.3. Financial Insights
16.3.1.4. Recent Developments
16.3.1.5. SWOT Analysis
16.3.2. Merck KGaA
16.3.3. Agilent Technologies, Inc.
16.3.4. Genscript Biotech Corporation
16.3.5. CRISPR Therapeutics AG
16.3.6. Editas Medicine
16.3.7. Intellia Therapeutics, Inc.
16.3.8. Beam Therapeutics Inc.
16.3.9. Caribou Biosciences, Inc.
16.3.10. Lonza Group, Ltd.
Data Collection
Primary Research & Secondary Research
Bottom-Up Approach & Top-Down Approach
Market Analysis & Size Estimation
Quality Check & Final Review
By Product & Services
• CRISPR kits & enzymes
• CRISPR libraries
• Other products
• gRNA design & vector construction
• Cell line engineering
• Screening services
• Other services
By Application
• Drug discovery & development
• Agriculture
• Others
By End User
• Pharmaceutical & biotechnology companies
• Academic & research institutes
• Others
© NextGen Intelligence Stats and Consulting LLP All rights reserved.
